Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | GPR39 | O43194 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318696 | 0.75 | NPC1 (0.44) | LMNAMAPTPKMNPC1MAP3K14 | |
| SCHEMBL31539133 | 0.72 | MAP3K14 (0.38) | LMNAMAPTPKMNPC1MAP3K14 | |
| SCHEMBL9510783 | 0.71 | MAP3K14 (0.40) | LMNAMAPTPKMNPC1MAP3K14 | |
| SCHEMBL1949591 | 0.69 | LMNA (0.41) | LMNAMAPTPKMNPC1MAP3K14 | |
| SCHEMBL1280223 | 0.68 | LMNA (0.40) | LMNAMAPTPKMNPC1MAP3K14 | |
| SCHEMBL8348991 | 0.67 | MAP3K14 (0.48) | LMNAMAPTPKMNPC1MAP3K14 | |
| SCHEMBL10754755 | 0.67 | MAP3K14 (0.48) | LMNAMAPTPKMNPC1MAP3K14 | |
| SCHEMBL11886046 | 0.67 | MAP3K14 (0.33) | LMNAMAPTPKMMAP3K14 | |
| SCHEMBL1273192 | 0.66 | MAP3K14 (0.35) | LMNAMAPTPKMMAP3K14 | |
| SCHEMBL20589363 | 0.64 | PRKCA (0.38) | LMNAMAPTPKMMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027453-B1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2021778-B1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-8389298-B2 | Methods using novel chemiluminescent labels | LUMIGEN, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8377647-B2 | Nonseparation assay methods | BECKMAN COULTER, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120094313-A1 | Nonseparation Assay Methods | BECKMAN COULTER, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8124362-B2 | Nonseparation assay methods | BECKMAN COULTER, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110318747-A1 | Nonseparation Assay Methods | BECKMAN COULTER, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269156-A1 | Nonseparation Assay Methods | BECKMAN COULTER, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8012705-B2 | Nonseparation assay methods | BECKMAN COULTER, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110183361-A1 | Nonseparation Assay Methods | BECKMAN COULTER, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7682839-B2 | Methods using novel chemiluminescent labels | LUMIGEN, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2021778-A4 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2027453-A4 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2027453-A1 | NONSEPARATION ASSAY METHODS | Beckman Coulter, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-2021778-A1 | NONSEPARATION ASSAY METHODS | Beckman Coulter, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007134098-A1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133988-A1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070264664-A1 | Nonseparation assay methods | NEXGEN DIAGNOSTICS LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070264665-A1 | Nonseparation assay methods | BECKMAN COULTER, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070172878-A1 | Methods using novel chemiluminescent labels | LUMIGEN, INC. | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172878-A1 | Methods using novel chemiluminescent labels | HLCS, LANCL1, ACR | LMNA 904/4885MAPT 4797/4885PKM 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.